PBAC's latest decision on Glycopyrronium: Recommended with restriction (2025). Considered for Treatment of severe primary axillary hyperhidrosis (PAHH) in patients aged 18 years and older who have previously failed or are intolerant to topical aluminium chloride treatment.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults aged 18 years and older with severe primary axillary hyperhidrosis who have previously failed topical aluminium chloride treatment after one to two months or are intolerant to it.
Therapy area
Dermatology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
ORR
Key trials
Hyp1-18/2016
Comparator
Botulinum toxin type A (BTA); secondary comparator: placebo/no treatment
Economic model
CEA
ICER note
No explicit ICER stated in the document. The submission presented a side-by-side cost-effectiveness analysis based on cost per responder rather than a traditional incremental cost-effectiveness ratio.